Background {#s1}
==========

Since 2004, the World Health Organization (WHO) has recommended a package of intermittent preventive treatment (IPTp) and insecticide treated nets (ITNs) together with effective management of clinical malaria and anaemia for malaria prevention and control during pregnancy in areas of stable malaria transmission in sub-Saharan Africa [@pone.0092102-World1]. Until 2012, WHO recommended two doses of sulphadoxine-pyrimethamine, (SP) administered in the second and third trimesters of pregnancy [@pone.0092102-World1]. These interventions can substantially reduce disease burden and adverse outcomes of malaria in pregnancy [@pone.0092102-Menendez1]--[@pone.0092102-Gamble1], and are inexpensive and cost effective [@pone.0092102-Worrall1]. Although these interventions have been available for over two decades [@pone.0092102-Menendez1]--[@pone.0092102-Gamble1], access to and use by pregnant women remains unacceptably low [@pone.0092102-vanEijk1].

The Roll Back Malaria Partnership aims to ensure that by 2015, all pregnant women living in areas of high-intensity transmission in sub-Saharan Africa receive IPTp and use ITNs [@pone.0092102-Roll1]. IPTp with SP is delivered to pregnant women through antenatal clinics (ANC) alongside ITNs. Despite almost universally high levels of ANC coverage in sub-Saharan Africa, coverage estimates for IPTp and ITNs in sub-Saharan Africa have increased only modestly between 2007 and 2010, from 13.6% to 21·5% and from 17.0% to 38·8% for IPTp and ITNs respectively, representing substantial missed opportunities at ANC [@pone.0092102-vanEijk1]. According to the Countdown to 2015 Decade Report, in 20 countries with data, IPTp and ITNs, together with case management of malaria during pregnancy, have the lowest coverage among all the interventions delivered to pregnant women at ANC [@pone.0092102-Countdown1]. The reasons for this are diverse and stem from barriers to delivery as well as user behaviours, as described in a recent systematic review of the factors affecting the delivery, access and use of IPTp and ITNs [@pone.0092102-Hill1]. For example two studies reported that health workers do not always offer IPTp to women at ANC [@pone.0092102-Sangare1], [@pone.0092102-Nganda1]. It is a particular concern that health services have been unable to deliver IPTp-SP effectively, as this relatively simple and cost effective regimen will most likely be replaced with more complicated and expensive drug regimens or new strategies [@pone.0092102-Tagbor1] in the near future due to increasing resistance to SP [@pone.0092102-terKuile1], [@pone.0092102-Chico1]. These alternative prevention strategies will present even greater challenges for effective delivery or systems effectiveness [@pone.0092102-SmithPaintain1], [@pone.0092102-Smith1].

A recent systematic review identified very few studies that evaluated the effectiveness of the delivery of IPTp [@pone.0092102-Gross1] and ITNs [@pone.0092102-Marchant1], [@pone.0092102-Webster1] through ANC. New methods are required to measure the relative impact of the different barriers to the delivery of these important interventions in order that programme managers can achieve the best value for money by prioritising which barriers to target in order to improve uptake. This study used household survey data to measure the effectiveness of the delivery of IPTp-SP and ITNs to pregnant women through ANC in one district in Mali, and assessed the predictors of effective delivery.

Methods {#s2}
=======

Ethical Considerations {#s2a}
----------------------

The study was approved by the ethical committees of the Faculty of Medicine, Pharmacy and Odonto-stomatology of Bamako, the Liverpool School of Tropical Medicine, and the London School of Hygiene and Tropical Medicine. Written informed consent was obtained from women prior to being interviewed at home and for adolescents who were not considered mature minors (a person under 18 years of age who is pregnant, married or a parent), written informed consent was obtained from the head of the household.

Study Area {#s2b}
----------

The household survey was conducted as part of a larger study to identify and quantify the major barriers to the scale up and use of interventions to control malaria in pregnancy at the district, facility, and community levels in Mali. The study was conducted in Segou District, Segou Region. Malaria in Segou Region is seasonal ranging from holo-endemic in the southern part of the district and meso-endemic to the north. HIV prevalence is 1.3% in the general population of Segou and 1.7% in women aged 15--49 years [@pone.0092102-CelluledePlanificationetde1]. Segou District has a total population of 448,552 projected from the 1998 census, with more than 60% of this population living in rural areas. The most common ethnic groups are Bamanan and Sarakole/Soninke, and the main economic occupation of the occupants is subsistence agriculture.

The health care system in Mali is severely under-resourced. The government funds health facilities down to district level only, comprising one hospital and one district level health centre termed the Centre de Santé de Reference (CSRef). All health facilities below this level, at what is termed the operational level, are funded by communities themselves through a concept developed initially as the 'Bamako Initiative' [@pone.0092102-Ridde1]. This engagement was done to push external partners and the government to transfer responsibility to the community for the creation, organisation and management of community health services (CSCom) through the ASACO (community health association) created in each 'health area'. At the time of the study, Segou District had a total of 26 functioning health structures, 18 of which were owned by the community (i.e. headed by a nurse paid by the community) and 8 of which were headed by a physician paid by the government. The government facilities comprised 1 hospital and 1 district level health facility (CSRef) based in Segou town (district headquarters).

Malaria in pregnancy services provided through Consultation Prénatale (CPN, or ANC) include 2 doses of IPTp administered by directly observed therapy (DOT) between month 4 and 8 (inclusive) gestation, with each dose given at least one month apart, and 3 doses for women who are HIV positive, and provision of a free long-lasting insecticide treated net (LLIN) to all women at first ANC visit in areas of high transmission [@pone.0092102-Programme1].

National level Demographic and Health Survey (DHS) data available at the time the study was designed (DHS 2006) showed that 63% of women made two or more ANC visits, 4% pregnant women received two doses of IPTp-SP during ANC visits and 39% of pregnant women used an ITN the night before the survey [@pone.0092102-CelluledePlanificationetde1]. The IPTp and ITN coverage figures for Segou Region were similar to the national average, with 3.8% of pregnant women reporting having received two doses of IPTp and 43% reporting having used an ITN the night before the survey.

Study Design and Selection of Study Participants {#s2c}
------------------------------------------------

A two stage cluster sampling household survey was undertaken over a period of 3 weeks in September 2009 during the rainy season. Enumeration areas from the 1998 census were used to select 40 villages, representing clusters, with probability proportional to size. The primary endpoint for sample size calculation was the proportion receiving 2-doses of IPTp. A sample size of 213 women of child-bearing age (15--49 years) was sufficient to estimate an uptake of 50%, with a precision of 6%, a design effect of 1.75 and 10% non-response. To obtain an evaluable sample of 213 women, the initial sample size was set at 624 [@pone.0092102-Baiden1] based on the hypothetical assumptions that 53% of women attending ANC are offered the first dose of IPTp, of which 99% take it, of which 65% return for a second ANC visit, of which 100% receive the second dose of IPTp (624×0.53×0.99×0.65 = 213).

A total of 16 households were randomly selected within each cluster using a modified EPI sampling technique. By using this method the sample was self weighted. One respondent within each household was selected using a set of predefined criteria as follows: women must be aged 15--49 years; pregnant women were prioritised over mothers of children aged under one year, who were prioritised over other non-pregnant women; and if more than one woman was currently pregnant/mother of a child aged under one year/aged 15--49 years, the woman most closely related to the head of the household was interviewed (i.e. wife\> daughter\> sister\> niece/aunt\> daughter-in-law).

Data Collection Instrument {#s2d}
--------------------------

The questionnaire sought to obtain key coverage indicators on the frequency and timing of ANC attendance, the frequency, timing and source of IPTp-SP doses with or without DOT, ITN use during the current/most recent pregnancy and source. Additional questions explored women's knowledge of malaria in pregnancy in relation to use of IPTp and ITNs, and whether HIV status alters behaviour patterns and uptake. A composite malaria knowledge score was created based on the cumulative score of correct responses in relation to source of malaria (mosquitoes), consequences of malaria in pregnancy to mother (anaemia) and unborn child (miscarriage, low birth weight (LBW), premature birth, still birth) and of methods to prevent malaria in pregnancy (e.g. ITNs, nets and/or ITNs). HIV status was self-reported, and additional indirect questions about recognition and use of cotrimoxazole and history of episodes of opportunistic infections associated with HIV were included. Self-reported IPTp, ITN and ANC practices, including HIV testing and results, were compared with data contained in ANC cards where available. Recording of household assets to develop a wealth index and observation of household ITNs *in situ* was also performed. Principle components analysis was used to construct a wealth index in order to assess the effect of socio-economic status (SES) [@pone.0092102-Filmer1], [@pone.0092102-Vyas1]. Household characteristics such as education of the household head, floor material, source of drinking water, type of toilet facility, household ownership, cooking fuel type, and ownership of a television and watch were used in the Principle components analysis.

The questionnaire was translated and back translated to ensure accuracy of translation of concepts and variables, and then pre-tested. Interviewers were trained to conduct the interviews in the national spoken language of Bambara, translated directly from the French translation of the questionnaire.

Data Processing and Analysis {#s2e}
----------------------------

Data from the household surveys were collected on personal digital assistants. All analyses were adjusted for the survey design and clustering of households using STATA 11.

This analysis was restricted to pregnant women and mothers of children under one year, termed 'recently pregnant women', given likely use and potential recall of IPTp and ITNs. Socio-demographic characteristics of currently and recently pregnant women were described and compared. Proportions of women accessing ANC, receipt and timing of each dose of IPTp-SP from any source and receiving ITNs from any source were quantified. The indicator for ITN use in currently pregnant women was the proportion of pregnant women who reported having used an ITN the night before the survey [@pone.0092102-World2], [@pone.0092102-RollBack1], and for recently pregnant women, the proportion of women who reported having used an ITN regularly during their most recent pregnancy [@pone.0092102-Gikandi1], [@pone.0092102-Guyatt1].

We used a framework developed previously for effectiveness analysis, adapted specifically for the delivery of IPTp-SP and ITNs through ANC to measure delivery system effectiveness using household data to identify critical points in the delivery system which were ineffective [@pone.0092102-Hill1]. The systems effectiveness analysis was undertaken using women who had been recently pregnant. We excluded HIV positive women with documented use of cotrimoxazole, since IPTp with SP is not recommended for women taking cotrimoxazole due to potential severe adverse events caused by concomitant use of two sulphur-containing drugs [@pone.0092102-World1]. Systems effectiveness was defined as the proportion of women attending ANC who reported having received a full course of IPTp-SP (two doses of SP) and having used an ITN regularly during the most recent pregnancy. Two categories of effectiveness analyses were applied - 'intermediate process effectiveness' and 'cumulative systems effectiveness' [@pone.0092102-Webster2]. Intermediate process effectiveness represents coverage of women at each of the intermediate steps in the delivery of IPTp-SP, with the addition of 'used an ITN' and then 'used an ITN from ANC' together with taking the second dose of IPTp as the final process. Intermediate process effectiveness was calculated as the number of women who successfully completed the intermediate process (the numerator) as a proportion of all women who reached that point in the delivery system (the denominator). An intermediate process was described as ineffective if ≤80% women successfully completed that step. Cumulative systems effectiveness represents successful coverage of women for each of the intermediate steps up to that point in the delivery system. The final step represents the percent of eligible women in the community that received both interventions and is equivalent to a cumulative coverage indicator for several indicators (two ANC visits, two doses of SP (IPTp) and ITN use) that are measured by DHS.

The effectiveness analyses for IPTp were performed on women first attending ANC in an eligible month of gestation (4 to 8 months) for IPTp and excluded women who were taking cotrimoxazole as documented on ANC cards. We did not take into account the dosing interval. These analyses were conducted under two scenarios, Scenario A where the criteria of receiving IPTp-SP by DOT was not included, and Scenario B where receiving IPTp-SP by DOT was included. The systems effectiveness analysis for ITNs was not restricted by gestational age as policy states ITNs are to be delivered to women at their first ANC visit regardless of gestational age.

Univariate analyses of potential predictors of receipt of: i) at least one ANC visit between 4--8 months gestation ii) two doses of IPTp-SP (with or without DOT); iii) one dose of SP by DOT; and iv) two doses of SP by DOT (as the four least effective processes identified), were conducted. Logistic regression models for survey design were used, and adjusted Wald tests were applied to test for associations between predictors and outcomes. Predictors of ITN use explored included selected individual and household socio-demographic factors (women's age, marital status, education, malaria knowledge using the composite malaria knowledge score, residence, and SES); person: net ratio stratified according to any net, ITNs, and LLIN; gravidity; losing a live born child; number and timing of ANC visits; whether they recently had a malaria episode and whether they took medicine for that episode. Potential predictors significant at the 10% level (p≤0.1) in the univariate analyses were included in multivariable logistic models to determine which factors were associated with the outcomes after accounting for other potential predictors. Interactions between paired predictors were assessed for all predictors included in the models.

We estimated the potential and actual effectiveness of the IPTp strategy on LBW extrapolated to the pregnant population of Segou Region (n = 116,813). We used the protective efficacy of IPTp on LBW of 35% among women protected by 2-doses of IPTp-SP and an ITN in any pregnancy observed in a cross sectional study from 2007 to 2009 in 5 districts of Mali (adjusted prevalence ratio (APR) 0.57; 95% CI 0.40, 0.80) and an incidence of LBW of 12% in women not receiving IPTp (Kassoum Kayentao, personal communication), and co-coverage with IPTp by DOT and ITNs, using the following formula [@pone.0092102-Chandramohan1]:

Results {#s3}
=======

Study Population {#s3a}
----------------

A total of 637 women of childbearing age were interviewed (99.5% response rate) of which 150 were pregnant (24%) and 264 (41%) were recently pregnant women. Among the pregnant women, the majority were in their second or third trimester (87%, 132/150) and the mean gestational age was 6 months (IQR 4--8) ([Table 1](#pone-0092102-t001){ref-type="table"}). The majority of women were multigravidae, with a median number of births in the pregnant and recently pregnant groups of 3 (IQR 2--6) and 4 (IQR 2--6) respectively. The median age was 27 years (IQR 22--30) among pregnant women and 25 years (IQR 21--30) among recently pregnant women. The majority of women in both groups were married (\>90%), and lived in rural areas (\>67%). The main ethnic group was Bambara (\>55%) and about two-thirds of women had no education (\>62%). Almost half (45%; 60/134, 16 missing values) of pregnant women and over a third of recently pregnant women (37%; 99/265) had lost a live born child. Self reported HIV prevalence was very low, 0% among pregnant women and 2% (1/50) among recently pregnant women.

10.1371/journal.pone.0092102.t001

###### Socio-demographic characteristics of the respondents.

![](pone.0092102.t001){#pone-0092102-t001-1}

  Socio-demographic data                         Pregnant women (N = 150)           Recently pregnant women (N = 264)            
  ------------------------------------- ------------------------------------------ ----------------------------------- --------- ------------------
  **Trimester**                                                                                                                  
  1^st^ trimester                                           19                                    12.7                           
  2^nd^ trimester                                           62                                    41.3                           
  3^rd^ trimester                                           70                                    46.0                           
  Median months gestational age                            150                                6 (IQR 4--8)                       
  **Gravidity**                                                                                                                  
  Gravida 1                                                 16                                    10.7                    47            18.4
  Gravida 2                                                 20                                    13.3                    48            18.8
  Gravida 3\>                                              114                                    76.0                    160           62.8
  Median number of births                                  150                                3 (IQR 2--6)                264       4 (IQR 2--6)
  **Age group (15--49 years)**                                                                                                   
  15to19                                                    23                                    15.3                    46            17.4
  20to24                                                    27                                    18.0                    61            23.1
  25to29                                                    47                                    31.3                    64            24.2
  30to34                                                    34                                    22.7                    56            21.2
  35to39                                                    11                                     7.3                    24            9.1
  40+                                                       8                                      5.3                    13            4.9
  Median Age                                                                                 27 (IQR 22--30)                      25 (IQR 21--30)
  **Marital status**                                                                                                             
  Married                                                  145                                    96.7                    245           92.8
  Divorced/separated                                        1                                      0.7                     0            0.0
  Single                                                    4                                      2.7                    19            7.2
  **Location of residence**                                                                                                      
  Urban                                                     45                                    30.0                     6            32.6
  Rural                                                    105                                    70.0                    178           67.4
  **Education level**                                                                                                            
  None/nursery                                             100                                    66.7                    164           62.1
  Primary                                                   46                                    30.7                    83            31.4
  Secondary/College/University                              4                                      2.7                    17            6.4
  **Ethnic Group**                                                                                                               
  Bambara                                                   87                                    58.0                    146           55.3
  Peulh                                                     16                                    10.7                    38            14.4
  Malinke                                                   4                                      2.7                     8            3.0
  Bozo/Somono                                               4                                      2.7                     5            1.9
  Dogon                                                     1                                      0.7                     4            1.5
  Other                                                     38                                    25.3                    63            23.9
  **HIV status (self reported)**                           0/32                                     0                    1/50     2.0 (0.3, 14.2)
  **Women with child aged \<1 year**      5/134[\*](#nt102){ref-type="table-fn"}             3.7 (1.6, 8.5)             264/264      100.0 (−)
  **Women with child aged \<5 years**    110/134[\*](#nt102){ref-type="table-fn"}            82.1(74.0,88.1)            264/264      100.0 (−)
  **Woman has lost a child**             60/134[\*](#nt102){ref-type="table-fn"}            44.8 (36.1,53.8)            99/264    37.5 (30.5,45.1)

N, denominator; n, numerator; CI, confidence interval; IQR, inter-quartile range; HIV, human immunodeficiency virus.

\*excludes primigravid women.

Coverage Indicators {#s3b}
-------------------

### Access to ANC and timing of first ANC visit {#s3b1}

Among recently pregnant women, 81% (215/264) of women reported attending ANC at least once, 75% (198/264) at least twice and 42% (112/264) made four or more visits, with a median number of 4 ANC visits (IQR 3--5) ([Table 2](#pone-0092102-t002){ref-type="table"}). Just over 40% of women first attended ANC in their first trimester, with almost half initiating attendance in their second trimester (47%) ([Figure 1](#pone-0092102-g001){ref-type="fig"}). Attendance among pregnant women was lower (63% for one visit and 43% for two visits), with a median of 2 visits (IQR 1--3), as would be anticipated given that 54% of women were still in their first or second trimester ([Table 2](#pone-0092102-t002){ref-type="table"}). The median month of gestation at first ANC visit was 4 months in both groups of women (IQR 3--5).

![Timing of first ANC visit among recently pregnant women who attended ANC (N = 215).\
ANC, antenatal clinic.](pone.0092102.g001){#pone-0092102-g001}

10.1371/journal.pone.0092102.t002

###### Key coverage indicators for ANC attendance and malaria in pregnancy interventions among pregnant and recently pregnant women.

![](pone.0092102.t002){#pone-0092102-t002-2}

  Coverage Indicators                                                   Pregnant women (N = 150)   Recently pregnant women (N = 264)                                                               
  -------------------------------------------------------------------- -------------------------- ----------------------------------- ---------------------------------------- ------------------- -------------------
  **Number ANC visits**                                                                                                                                                                            
  At least one visit                                                             94/150                    62.7 (52.8, 71.6)                          215/264                   81.4 (75.2,86.4)   
  At least two visits                                                            64/150                    42.7 (33.6, 52.2)                          198/264                   75.0 (68.2, 80.8)  
  4 or more visits                                                               23/150                    15.3 (9.7, 23.4)                           112/264                   42.4 (34.6, 50.6)  
  Median number of ANC visits among ANC attendees                                  94                        2 (IQR 1--3)                               215                       4 (IQR 3--5)     
  **Gestational age at 1^st^ ANC visit**                                                                                                                                                           
  0--3 months                                                                    34/93                     36.6 (25.6,49.1)                            88/215                   40.9 (33.0,49.3)   
  4--6 months                                                                    53/93                     57.0 (45.8,67.5)                           102/215                   47.4 (40.4,54.6)   
  7--9 months                                                                     6/93                      6.5 (2.7,14.5)                             25/215                    11.6 (7.2,18.2)   
  Median gestational age at 1^st^ ANC visit                                        92                        4 (IQR 3--5)                               208                       4 (IQR 3--5)     
  **1 dose SP** [†](#nt104){ref-type="table-fn"}                                                                                                                                                   
  1 dose (all trimesters, any source)                                                                                                                 199/264                   75.1 (68.3, 80.8)  
  1 dose (4--8 months, any source)                                                                                                                    150/264                   56.6 (50.1, 62.9)  
  Dose 1 at ANC (all trimesters)                                                                                                                      177/199                   88.9 (83.3, 92.8)  
  Dose 1 by DOT at ANC (all trimesters)                                                                                                60/173[≠](#nt105){ref-type="table-fn"}   33.9 (23.6, 46.0)  
  **2 doses SP** [†](#nt104){ref-type="table-fn"}                                                                                                                                                  
  2 doses (all trimesters, any source)                                                                                                                115/262                   43.4 (36.5, 50.5)  
  2 doses (4--8 months, any source)                                                                                                                   103/262                   38.9 (32.5, 45.7)  
  Dose 2 at ANC (all trimesters)                                                                                                                      110/115                   96.7 (90.0, 98.2)  
  Dose 2 by DOT at ANC (all trimesters)                                                                                                28/108[≠](#nt105){ref-type="table-fn"}   25.5 (17.2, 36.0)  
  **3 doses SP** [†](#nt104){ref-type="table-fn"}                                                                                                                                                  
  3 or more doses (all trimesters, any source)                                                                                                         21/260                    8.1 (4.8, 13.2)   
  **ITN use (amongst sampled women)**                                                                                                                                                              
  ITN used last night                                                           138/149                    92.6 (84.7, 96.6)                                                                       
  ITN used during last pregnancy                                                                                                                      242/263                   92.0 (83.0, 94.8)  
  ITN sourced from ANC clinic                                                   102/138                    73.9 (65.8, 80.7)                          196/242                   81.0 (75.4, 85.6)  
  **Co-coverage IPTp** [†](#nt104){ref-type="table-fn"} **and ITNs**                                                                                                                               
  **1 dose SP**                                                             No IPTp1, No ITN                                                                                         10/262          3.8 (2.0, 7.1)
                                                                             IPTp1, No ITN                                                                                           11/262          4.2 (2.2, 7.7)
                                                                             No IPTp1, ITN                                                                                           53/262         20.2 (15.1, 26.6)
                                                                            Both IPTp1 & ITN                                                                                         188/262        71.5 (65.2,77.0)
  **2 doses SP**                                                            No IPTp2, No ITN                                                                                         14/260          5.3 (3.1, 8.9)
                                                                             IPTp2, No ITN                                                                                            7/260          2.7 (1.2, 5.9)
                                                                             No IPTp2, ITN                                                                                           131/260        50.4 (43.0, 57.8)
                                                                            Both IPTp2& ITN                                                                                          108/260        41.5 (35.2, 48.2)

IPTp1, one dose of SP; IPTp2, two doses of SP; DOT, directly observed therapy; ITN, insecticide treated net; ANC: antenatal clinic; IPTp, intermittent preventive treatment; N, denominator; n, numerator; CI, confidence interval; IQR, inter-quartile range; SP, sulfadoxine-pyrimethamine.

Excludes women who did not receive IPTp and who were taking cotrimoxazole as documented on ANC cards.

missing records.

### Number of IPTp doses and timing of receipt {#s3b2}

Three-quarters of recently pregnant women (not taking cotrimoxazole) reported receiving one dose of SP in any trimester from any source (75%; 199/264), and 57% (150/264) in women who received doses in an eligible month ([Table 2](#pone-0092102-t002){ref-type="table"}). The majority of women reported receiving the first dose of SP at ANC (89%; 177/199) but only 34% said they received it under DOT (60/173, 4 missing values). Only 43% (115/262) of recently pregnant women reported receiving the recommended second dose of SP (any trimester, any source), and only 39% (103/262) in an eligible trimester. The majority (97%) of women reported receiving the second dose of SP from ANC of which only a quarter (26%) reported receiving it by DOT. A small proportion of women (8%) reported receiving three doses of SP in any trimester from any source.

### IPTp coverage by number and timing of ANC visits {#s3b3}

Among recently pregnant women the mean number of doses of SP showed an increasing trend with increasing number of ANC visits. Similarly, the number of doses of SP received was associated with gestational age at first ANC visit, with fewer recently pregnant women receiving a second dose of SP if they first attended ANC in their second or third trimesters (p = 0.01) ([Figure 2](#pone-0092102-g002){ref-type="fig"}).

![Number of IPTp doses received by trimester at 1^st^ ANC visit among recently pregnant women.\
IPTp, intermittent preventive treatment; ANC, antenatal clinic.](pone.0092102.g002){#pone-0092102-g002}

### ITN use and co-coverage with ITNs and IPTp {#s3b4}

Among pregnant women, 93% (138/149) reported using an ITN the previous night and similarly 92% (242/263) of recently pregnant women reported using an ITN regularly during their most recent pregnancy. Approximately three-quarters of women in both groups reported obtaining the net used in pregnancy from ANC (74% and 81% of pregnant and recently pregnant women respectively). In terms of co-coverage of ITN use and IPTp receipt among recently pregnant women, 72% (188/262) reported using an ITN and receiving one dose of SP and 42% (108/260) of using an ITN and receiving two doses of SP. Whilst few women reported using neither ITN nor one or two doses of SP (4% and 5% respectively), a large proportion of women reported using an ITN alone in the absence of any SP, with 20% (53/262) and 50% (131/260) of ITN users who reported not having received one and two doses of SP respectively.

System Effectiveness of IPTp and ITN Delivery through ANC {#s3c}
---------------------------------------------------------

### IPTp with or without DOT {#s3c1}

Although 81% of recently pregnant women visited ANC at least once ([Table 1](#pone-0092102-t001){ref-type="table"}), only 59% (125/213) of women not taking co-trimoxazole made their first ANC visit in an eligible gestational age for receiving IPTp ([Figure 3](#pone-0092102-g003){ref-type="fig"}). Of these, 82% (102/125) received the first dose of SP, and of the 91% (93/102) of women who returned for a second ANC visit, only 66% (61/92) received a second dose ([Table 3](#pone-0092102-t003){ref-type="table"}). Only 24% (55/213) of women received the recommended two doses of SP and used an ITN during pregnancy. There were two intermediate processes in the delivery system that were ≤80% effective -- women first attending ANC in an eligible gestational age for IPTp, and the receipt of the second dose of SP. ITN use among women receiving two doses of SP was \>90%.

![Cumulative effectiveness† of ANC to deliver IPTp and ITNs among recently pregnant women.\
IPTp, intermittent preventive treatment; IPTp1, first dose; IPTp2, second dose; ANC, antenatal clinic; DOT, directly observed therapy; ITN, insecticide treated net. †Cumulative systems effectiveness represents successful coverage of women for each of the intermediate steps up to that point in the delivery system.](pone.0092102.g003){#pone-0092102-g003}

10.1371/journal.pone.0092102.t003

###### Intermediate process and cumulative effectiveness± of receiving two doses of SP and using an ITN with and without DOT in an eligible gestational age (4--8 months) among recently pregnant women not taking co-trimoxazole.

![](pone.0092102.t003){#pone-0092102-t003-3}

                                                                                    2 doses of SP   2 doses of SP by DOT                                                                                            
  -------------------------------------------------------------------------------- --------------- ---------------------- ------------------- ------ ------------------------------------ ----- ------------------- ------
  **Attend ANC at least once**                                                           213                125            58.7 (50.3, 66.6)   58.7                  213                   125   58.7 (50.3, 66.6)   58.7
  **Took IPTp1**                                                                         125                102            81.6 (72.1, 88.4)   47.9                  125                   102   81.6 (72.1, 88.4)   47.9
  **Took IPTp1 by DOT**                                                                                                                               91[†](#nt107){ref-type="table-fn"}   30    33.0 (19.7, 49.7)   15.8
  **Attend ANC at least twice**                                                          102                 93            91.2 (82.2, 95.8)   43.7                   30                   29    96.7 (77.4, 99.6)   15.3
  **Took IPTp2**                                                                         92                  61            66.3 (57.4, 74.2)   29.0                   29                   15    51.7 (34.3, 68.7)   7.9
  **Took IPTp2 by DOT**                                                                                                                                               15                   12    80.0 (49.9, 95.1)   6.3
  **Took IPTp2 & used an ITN** **during last pregnancy**                                 61                  55            90.2 (78.2, 95.9)   26.2                                                                 
  **Took IPTp2 & used an** ***[ANC]{.ul}*** **ITN** **during last pregnancy**            55                  51            92.7 (81.6, 97.3)   24.3                                                                 
  **Took IPTp2 by DOT & used an** ***[ANC]{.ul}*** **ITN during last pregnancy**                                                                                      12                   11    91.7 (46.8, 99.3)   5.8

IPTp1: one dose of SP; IPTp2: two doses of SP; DOT: directly observed therapy; ITN: insecticide treated net; ANC: antenatal clinic; IPTp, intermittent preventive treatment; SP, sulfadoxine-pyrimethamine; N, denominator; n, numerator; CI confidence interval.

11 missing records.

Intermediate process effectiveness represents coverage of women at each of the intermediate steps in the delivery of IPTp;

Cumulative systems effectiveness represents successful coverage of women for each of the intermediate steps up to that point in the delivery system.

### IPTp given by DOT {#s3c2}

With respect to DOT, the cumulative system effectiveness was substantially lower, with only 6% of women receiving two doses of SP by DOT and using an ITN ([Table 3](#pone-0092102-t003){ref-type="table"}) ([Figure 3](#pone-0092102-g003){ref-type="fig"}). The intermediate processes that were ≤80% effective were, in addition to first attending ANC in an eligible gestational age for IPTp, receipt of the first dose of SP under DOT (33%), receipt of a second dose of SP (52%) and receipt by DOT (80%). ITN use among women receiving two doses of SP by DOT was 92%.

### ITNs {#s3c3}

Among the 81% of recently pregnant women who attended ANC at least once, 93% (200/215) reported using an ITN during their last pregnancy of which 85% (169/200) were obtained from ANC ([Table 4](#pone-0092102-t004){ref-type="table"}). Among the 63% (94/150) of pregnant women who attended ANC at least once, 95% (88/93) reported using an ITN the previous night, of which 86% (76/88) were sourced from ANC.

10.1371/journal.pone.0092102.t004

###### Intermediate process and cumulative effectiveness± of receiving an ITN from ANC among pregnant (all gestational ages) and recently pregnant women.

![](pone.0092102.t004){#pone-0092102-t004-4}

                                                                                  Pregnant women   Recently pregnant women                                                             
  ------------------------------------------------------------------------------ ---------------- ------------------------- ------------------- ------ ----- ----- ------------------- ------
  **1. Attend ANC at least once**                                                      150                   94              62.7 (52.8, 71.6)   62.7   264   215   81.4 (75.2, 86.4)   81.4
  **2. Used an ITN last night/during** **last pregnancy**                               93                   88              94.6 (87.5, 97,8)   58.7   215   200   93.0 (88.6, 95.8)   75.8
  **3. Used an** ***[ANC]{.ul}*** **ITN last night/during** **last pregnancy**          88                   76              86.4 (76.2, 92.6)   50.7   200   169   84.5 (78.1, 89.3)   64.0
  **Difference in coverage between** **process 1 and 3**                                                                                         12.0                                   17.4

N, denominator; n, numerator; CI, confidence interval; ITN: insecticide treated net; ANC: antenatal clinic.

±Intermediate process effectiveness represents coverage of women at each of the intermediate steps in the delivery of IPTp; ^≠^Cumulative systems effectiveness represents successful coverage of women for each of the intermediate steps up to that point in the delivery system.

Predictors of IPTp Receipt {#s3d}
--------------------------

### Two doses of SP {#s3d1}

The univariate predictors of recently pregnant women reporting having received two doses of SP were: number of ANC visits and timing of 1^st^ ANC visit ([Table 5](#pone-0092102-t005){ref-type="table"}). The odds of women reporting receipt of two doses of SP progressively decreased the later the woman made her first ANC visit (OR 0.24, 95% CI 0.09, 0.67 for 7--9 months vs. 1--3 months gestation) and increased with number of ANC visits (OR 12.00, 95% CI 1.71, 47.91 for 3 vs. 1 visit). After adjustment, no factors were independently associated with receipt of two doses of SP among recently pregnant women ([Table 5](#pone-0092102-t005){ref-type="table"}).

10.1371/journal.pone.0092102.t005

###### Univariate and multivariate analysis of predictors of receiving *two doses of IPTp* among recently pregnant women.

![](pone.0092102.t005){#pone-0092102-t005-5}

                                              Recently pregnant women (N = 263)                                                         
  ------------------------------------------ ----------------------------------- ------ ------- ------------ ------ ------ ------------ -----
  **Number of ANC visits**                                                                                    0.02                       0.1
  1 visit                                                    16                   12.5     1                          1                 
  2 visits                                                   28                   35.7   3.89    0.67,22.45          2.90   0.48,17.71  
  3 visits                                                   57                   63.2   12.00   2.24,64.40          8.00   1.33,48.30  
  4\> visits                                                 110                  56.4   9.04    1.71,47.91          6.14   1.01,37.41  
  **Timing of 1st ANC visit by trimester**                                                                    0.01                      
  0--3 months                                                86                   53.5     1                          1                  0.1
  4--6 months                                                102                  57.8   1.19    0.66,2.15           1.38   0.75, 2.55  
  7--9 months                                                23                   21.7   0.24    0.09,0.67           0.47   0.15, 1.45  
  **Malaria knowledge score**                                                                                 0.06                       0.3
  Score 1 (Lowest)                                           75                   32.0     1                          1                 
  Score 2                                                    94                   48.9   2.04    1.09, 3.82          1.90   0.85, 4.28  
  Score 3 (Highest)                                          92                   48.9   2.03    1.00,4.16           1.61   0.65,3.98   

N, denominator; n, numerator, OR, odds ratio; AOR, adjusted odds ration; CI, confidence interval ANC, antenatal clinic.

### One and two doses of SP by DOT {#s3d2}

The univariate predictors of recently pregnant women reporting that they received one dose of SP by DOT were SES and marital status, and for two doses of SP by DOT, marital status and distance to the local health facility ([Table 6](#pone-0092102-t006){ref-type="table"}). After adjustment, being unmarried was an independent predictor for receiving either dose of SP by DOT (AOR 0.10, 95% CI 0.03, 0.40 for married women receiving 2 doses by DOT), and women who lived \>5 km from the local health facility were also more likely to report receipt of two doses of SP by DOT (AOR 0.34, 95% CI 0.14, 0.83 for women living \<5 km from a health facility).

10.1371/journal.pone.0092102.t006

###### Univariate and multivariate analysis of predictors of receiving one and two doses of SP *under DOT* among recently pregnant women.

![](pone.0092102.t006){#pone-0092102-t006-6}

  Determinant                 1 dose SP under DOT (N = 174)   2 doses SP under DOT (N = 109)                                                                                                                     
  -------------------------- ------------------------------- -------------------------------- ------ ------------ ------- ------ ------------ ------ ----- ------ ------ ------------ ------- ------ ----------- -------
  **Married**                                                                                                      0.01                        0.03                                    0.005                      0.002
  No                                       11                              72.7                 1                           1                          7    71.4    1                           1                
  Yes                                      163                             31.9                0.18   0.04,0.70            0.19   0.04,0.85           102   22.6   0.12   0.03, 0.49           0.10   0.03,0.40  
  **SES**                                                                                                          0.095                       0.1                                                               
  1 most poor                              28                              14.3                 1                           1                                                                                    
  2                                        33                              30.3                2.61   0.71,9.55            2.19   0.59,8.11                                                                      
  3                                        41                              46.3                5.18   1.47,18.24           4.82   1.37,16.99                                                                     
  4                                        38                              42.1                4.36   1.37,13.85           3.85   1.17,12.71                                                                     
  5 least poor                             33                              33.3                3.00   0.85,10.58           2.54   0.69,9.37                                                                      
  **Distance to facility**                                                                                                                                                             0.03                       0.02
  ≥5 km                                                                                                                                               33    39.4    1                           1                
  \<5 km                                                                                                                                              76    19.7   0.38   0.16,0.90            0.34   0.14,0.83  

N, denominator; n, numerator, OR, odds ratio; AOR, adjusted odds ratio; CI, confidence interval ANC, antenatal clinic; DOT, direct observed therapy; SP, sulfadoxine-pyrimethamine; SES, socio-economic status; km, kilometres.

Predictors of ITN Use {#s3e}
---------------------

The univariate predictors of recently pregnant women reporting using an ITN in pregnancy were being married (OR 3.5, 95% CI 1.00, 12.60), age, distance form health facility and person: LLIN ratio. Adolescents were less likely to use ITNs than older women (OR 0.30, 95% CI 0.13, 0.74) as were women who lived \<5 km from a health facility (OR 0.32, 95% CI 0.10, 1.04) and who lived in a household with a high person: LLIN ratio (OR 0.26 95% CI 0.06, 1.12 for 4+ vs. \<2 persons per net) ([Table 7](#pone-0092102-t007){ref-type="table"}). After adjustment the only independent predictor for using an ITN among recently pregnant women was person: LLIN ratio (AOR 0.16 95% CI 0.04, 0.55 for 4+ household members per LLIN.

10.1371/journal.pone.0092102.t007

###### Univariate and multivariate analysis of predictors of *using an ITN* among recently pregnant women.

![](pone.0092102.t007){#pone-0092102-t007-7}

                                   Recently pregnant women (N = 263)                                                       
  ------------------------------- ----------------------------------- ------ ------ ------------ ------ ------ ----------- -------
  **Parity**                                                                                      0.06                       0.4
  Para 1                                           9                   77.8    1                          1                
  Para 2--4                                       123                  89.4   2.45   0.98,6.14           1.70   0.48,6.01  
  Para 5\>                                        131                  95.4                                                
  **Married**                                                                                     0.05                       0.7
  No                                              19                   79.0    1                          1                
  Yes                                             243                  93.0   3.5    1.00,12.60          1.46   0.26,8.06  
  **Adolescent**                                                                                  0.01                       0.2
  No                                              216                  94.0    1                          1                
  Yes                                             46                   82.6   0.30   0.13,0.74           0.43   0.10,1.84  
  **Person: LLIN ratio**                                                                          0.02                      0.004
  \<2                                             44                   95.5    1                          1                
  2--\<4                                          101                  96.0   1.15   0.21,6.25           0.82   0.18,3.65  
  4+                                              58                   84.5   0.26   0.06,1.12           0.16   0.04,0.55  
  **Took medicine for malaria**                                                                   0.09                     
  No                                              15                   80.0    1                          NA               
  Yes                                             133                  92.5   3.08   0.82,11.56                            
  **Distance to facility**                                                                        0.06                      0.09
  ≥5 km                                           86                   96.5    1                          1                
  \<5 km                                          176                  89.8   0.32   0.10,1.04           0.23   0.04,1.29  

N, denominator; n, numerator, OR, odds ratio; AOR, adjusted odds ratio; CI, confidence interval; LLIN, long lasting insecticide treated net; km, kilometres; NA, Not available due to non convergence.

Modelled Number of LBW Averted {#s3f}
------------------------------

The potential effectiveness of the malaria in pregnancy prevention strategy in averting LBW among the pregnant population of Segou Region was calculated using the effectiveness data from recently pregnant women not taking cotrimoxazole. This showed that 59% (126/214) made their first visit in an eligible trimester and 90% returned to ANC for a second visit (93/103) ([Table 3](#pone-0092102-t003){ref-type="table"}) and could thus be potential recipients of two doses of SP by DOT and use of an ITN; and result in a potential 2,914 cases of LBW averted. However, based on the reported co-coverage of two doses of SP by DOT and ITNs (5%; 11/214), actual effectiveness was only 252 cases of LBW averted. The difference between potential and actual effectiveness is 2,662 cases of LBW (95% CI 152--4,335) that may have been averted if all women in Segou Region who attended ANC at least twice had received IPTp by DOT and used an ITN, equivalent to 228 (95% CI 13--371) cases of LBW per 10,000 women.

Discussion {#s4}
==========

We have used household data to assess the ANC attendance patterns among pregnant women and the relative effectiveness of the health system in delivering IPTp and ITNs to women through ANC in Segou District in Mali. Whilst a high percentage of women made at least two ANC visits (75%), with a significant proportion of women initiating ANC attendance in their first or second trimester (88%), only a quarter of women received two doses of SP and used an ITN, and only 5% received both doses of SP by DOT and used an ITN. Both ANC attendance patterns among women and factors affecting the delivery of care at ANC contribute to the low effectiveness reported.

Women in this setting start their ANC visits earlier than reported in East Africa [@pone.0092102-Hill2], and return for multiple visits, suggesting a favourable pattern of behaviour for the delivery of ANC services. ANC attendance in the study was slightly higher than reported in the most recent Mali DHS [@pone.0092102-CelluledePlanificationetde1], with 75% compared to 63% of women making two or more ANC visits, a higher median of ANC visits (median of 4 compared to 3), and a higher proportion of women initiating ANC in their first trimester (41% compared to 30%, with a median of 4 months gestation). Therefore a high proportion of women were not eligible for the first dose of IPTp at their first ANC visit, which should only be given at the start of the second trimester.

Among the women who first attended ANC between 4--8 months gestation, a high proportion reported receiving one dose of SP, but only a third of doses were given by DOT. However, the majority of women who received a second dose of SP reported to have received it by DOT. The poor adherence to DOT, and the reasons for this, are described in a parallel study using observations and in-depth interviewers with health providers in a sample of health facilities in Segou District [@pone.0092102-Webster3], [@pone.0092102-Webster4]. Observation data collected in health facilities found provision of IPTp-SP by DOT to be very low, 0% and 34.3% (95% CI 10.5, 69.8) at district and community level health facilities, respectively. The main reason for poor adherence to giving IPTp by DOT reported by the majority of health workers interviewed was that they had decided, through personal experience, reports of pregnant women, training, or supervision that the side effects of SP were such that it should not be given to pregnant women on an empty stomach. It is possible that because the second dose of SP is given in the late second or third trimester, i.e. at a more advanced stage of pregnancy, that side effects and especially nausea, would be less prevalent hence the higher number of women who reported receiving the second dose by DOT. The incidence of side effects to SP by gestational age together with the perception of this by health workers requires further investigation. We undertook a similar study in Kenya where we found the least effective steps in the delivery of SP was receiving any SP, but when women did receive SP they were more likely to receive it by DOT than in Mali [@pone.0092102-Hill1]. This type of analysis can therefore by useful for highlighting these programmatic deficiencies, which vary from country to country and also within the same country.

Of concern is the finding that just over 20% of recently pregnant women reported receiving the first dose of SP in their first trimester, i.e. in an ineligible gestational age of pregnancy. This may to some extent reflect poor recall or knowledge among women, nevertheless ANC card data indicated a similar proportion of women were given IPTp in the first trimester, confirming that there was some practice of providers giving women the first dose of SP in their first trimester ([Figure 4](#pone-0092102-g004){ref-type="fig"}). Confusion among health providers over the timing of giving IPTp-SP has been described elsewhere [@pone.0092102-Hill3], and in the parallel study in Mali, some health providers stated that women of less than one month gestation, rather than 1^st^ trimester, should not be given SP [@pone.0092102-Webster3]. On the basis of a recent meta-analysis showing that three or more doses of SP are more effective than two doses [@pone.0092102-Kayentao1], WHO recently updated its policy guidance to recommend the administration of SP to pregnant women at every scheduled antenatal visit starting in the second trimester [@pone.0092102-World3]. The new guidance is more closely aligned with the new Focused Antenatal Care schedule of four visits in the second and third trimesters [@pone.0092102-World3], and is anticipated to simplify the strategy and improve uptake of IPTp-SP. The release of this simplified guidance provides an opportunity for countries to improve the delivery of IPTp-SP, and to retrain health providers to avoid administering SP in the first trimester.

![Documented and reported receipt of first and second dose of SP for IPTp by trimester among pregnant and recently pregnant women.\
IPTp, intermittent preventive treatment; SP, sulphadoxine-pyrimethamine.](pone.0092102.g004){#pone-0092102-g004}

As anticipated by the high ANC coverage data in Segou District, a high proportion of women returned to ANC for a further visit in an eligible gestational age after receiving the first dose of SP (\>90%). However, only just over half of these women reported receiving a second dose of SP. The two predominant reasons given by women for not taking the second dose of SP were that they were not offered it (42%, 22/52) and that they were not informed a second dose was necessary (37%; 19/52) (data not shown). It is also possible that women who initiate ANC late account for some of this drop in effectiveness, as shown in [Figure 2](#pone-0092102-g002){ref-type="fig"}; indeed timing of the first ANC visit was a predictor of receipt of two doses of SP in the univariate analysis. The exclusion of administering SP in the 9^th^ month of pregnancy results in a narrow window of opportunity to administer SP to women who initiate ANC late. In the parallel study among health workers, there was considerable misinterpretation of the guidelines, that the 8^th^ month was inclusive i.e. that SP could not be given in the 8^th^ or 9^th^ month, and that the first dose should be denied unless a women could make two scheduled visits for both doses before the end of her pregnancy [@pone.0092102-Webster3].

There were no statistically significant predictors of receiving two doses of SP in multivariate models, though both number (≥2 visits) and knowledge of malaria were associated with receipt in the univariate analysis, and late first ANC visit with non-receipt of SP. Predictors of receiving SP by DOT were marital status and distance from the health facility. Women who were married were less likely to receive either the first or second dose of SP by DOT, as were women who lived \<5 km from their local health facility less likely to receive two doses of SP by DOT. Some studies have reported that women need their husband's consent before taking drugs [@pone.0092102-Diala1], [@pone.0092102-Iliyasu1], and it may be that unmarried women are more likely to take SP by DOT as they do not need to wait for their husband's consent. Women who live close to a health facility may argue that they need to return home either to eat first, since women not wishing to take SP on an empty stomach was a problem observed by health providers in the parallel health facility study in Mali [@pone.0092102-Webster3], or to ask their husbands consent to take the drugs. Interestingly, less poor women were less likely to receive SP by DOT in the health facility study undertaken at the same time of the household survey [@pone.0092102-Webster4].

ITN use among pregnant and recently pregnant women in this setting was high, with over 90% of women who had attended ANC at least once reporting having used an ITN. The effectiveness analysis suggests that ANC is an effective channel for delivering ITNs to pregnant women, with 85% of pregnant and recently pregnant ITN users reporting having used an ITN from ANC. This is substantially higher use than reported in the 2006 DHS survey of 30% in Segou Region, as would be anticipated given ongoing scale up of the national ITN programme, and coverage was higher in rural areas compared to urban areas nationally (31% vs. 22%) [@pone.0092102-CelluledePlanificationetde1]. This is consistent with our finding that ITN use was lower among recently pregnant women living within 5 km of a health facility, which usually have a central location in a village or town. Married, multigravid women were more likely to use an ITN in the univariate analysis, and adolescents less likely to use ITNs, suggesting that adolescents should be a high risk group for targeting ITNs in this setting. This is consistent with a recent systematic review and meta-analysis which showed using data from 19 countries of sub-Saharan Africa that married, multigravid, older women aged \>19 years were the most likely to use an ITN [@pone.0092102-Hill3]. The only multivariate predictor in our analysis from Segou District was household person: LLIN ratio which concurs with findings from another study using standardized national surveys across 15 countries, which showed that intra-household access to ITNs was the strongest and most consistent determinant of use among children [@pone.0092102-Eisele1].

A limitation of household surveys is potential reporting bias among interviewees, who may over- or under-report access and usage of interventions for a number of reasons including poor recall; this may be a general limitation but one which might be anticipated with regard to gestational age, which is difficult to interpret in the first trimester and especially among primigravidae. We measured concordance between reported and documented information using ANC cards where available, obtained from both pregnant and recently pregnant women. We found good concordance between reported and documented data for timing of first ANC visit (Kappa score 0.6945) and receipt of two doses of SP (K 0.682), and fair concordance for mean gestational age for the first and second dose of SP (K 0.249 and 0.206 respectively) [@pone.0092102-Altman1]. There was potential selection bias among recently pregnant women; by selecting women with a child aged under one year, women who had had a pregnancy loss (miscarriage or stillbirth) may have been excluded from the recently pregnant group of women, and these women may have had different health seeking behaviours. Also, the diminishing numbers in the evaluative sample in the effectiveness analyses mean the regression analyses have less statistical power than anticipated. We use women's self-report to interpret health provider practices which may not reflect true events, hence findings are compared with those of the observation studies in health facilities in the parallel study in Mali, which support the main findings from our analysis [@pone.0092102-Webster3], [@pone.0092102-Webster4].

Conclusions {#s5}
===========

In conclusion, our analysis has shown that ANC is a more effective delivery channel for ITNs than for IPTp in this setting. This translates into a loss of community effectiveness of the IPTp strategy; with the current levels of coverage only 9% of the potential effectiveness of this strategy is being achieved, and a further 228 (95%) cases of LBW per 10,000 live births can be averted by achieving universal coverage of IPTp and ITNs. Loss in effectiveness is even greater if women who do not attend ANC were to be considered in this analysis. The practice among women of attending ANC early, an important element of focussed antenatal care, combined with evidence of health providers administering IPTp in the first trimester together with poor adherence to giving IPTp by DOT, points to the need to improve the quality of IPTp provision.
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